Sandesh Mahatme's most recent trade in Vor Biopharma Inc was a trade of 13,882,750 Common Stock done . Disclosure was reported to the exchange on July 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vor Biopharma Inc | Sandesh Mahatme | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jul 2025 | 13,882,750 | 13,882,750 | - | 0 | Common Stock | |
| CRISPR Therapeutics AG | Sandesh Mahatme | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Sandesh Mahatme | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| Aeglea BioTherapeutics Inc | Sandesh Mahatme | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 43,000 | 43,000 | - | - | Director Stock Option (right to buy) | |
| Aeglea BioTherapeutics Inc | Sandesh Mahatme | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 40,000 | 40,000 | - | - | Director Stock Option (right to buy) |